We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss
Read MoreHide Full Article
NuVasive, Inc. delivered first-quarter 2020 adjusted earnings per share (EPS) of 48 cents, reflecting a 9.4% decline from the year-ago quarter. However, the figure surpassed the Zacks Consensus Estimate by 37.1%. The one-time adjustments include expenses associated with certain ongoing litigation matters and amortization expenses among others.
On a reported basis, EPS came in at 10 cents, reflecting 44.4% decline from the year-ago number.
The year-over-yeardecline can be attributed to significantly lower revenues on a year-over-year basis due to the coronavirus outbreak.
Revenues in the first quarter totaled $259.9 million, down 5.4% year over year on a reported basis (down 5.1% at constant exchange rate or CER). The top line also lagged the Zacks Consensus Estimate by 2.6%.
Geographical & Segmental Details
In the reported quarter, the U.S. Spinal Hardware business revenues declined 6.3% year over year to $138.5 million. The company noted that in the first two months of the quarter, NuVasive's X360 system was tracking to deliver solid year-over-year growth. However, starting in mid-March, the U.S. Spinal Hardware business witnessed significant deferrals in elective surgical procedures due to COVID-19.
Revenues from the U.S. Surgical Support business were $64.3 million in the first quarter, down 10.9% year over year. Here too, Case volumes tracked up year over year in January and February. The business experienced a slowdown in volumes in mid-March due to the pandemic.
In the March-end quarter, the company registered international revenues of $57.1 million, reflecting 4.1% year-over-year growth at CER.This was driven by mid-double-digit growth in Asia-Pacific, led by Japan, where COVID-19 impact was nominal in this period.
Margin Details
In the reported quarter, gross profit declined 6.1% year over year to $188 million. Gross margin contracted 54 basis points (bps) to 72.3%. Adjusted operating profit improved 5% from the year-ago period to $39.5 million. Accordingly, adjusted operating margin expanded 151 bps to 15.2% in the January-March quarter.
Operational Update
The company exited the first quarter with cash and cash equivalents of $511.9 million compared with $213 million at the end of 2019. First-quarter net cash, provided by operating activities, totaled $5.2 million compared with the prior year period’s $24.5 million.
Guidance for 2020
On Apr 14, 2020, while announcing its COVID-19 business update, NuVasive noted that it iscurrently unable to predict the time and rate of recovery of its elective surgery volumes. This compelled the company to withdraw its 2020 guidance.
Our Take
NuVasive witnessed a significant fall in elective procedure volumes in the first quarter, which is expected to intensify in second-quarter 2020.
Given the adverse impact of the coronavirus pandemic on demand for elective surgical procedures, NuVasive is adopting measures to control its expenses and overcome the situation. However, given that technological innovation is the key growth driver, NuVasive intends to maintain its levels of R&D investment.
NuVasive currently carries a Zacks Rank #4 (Sell).
Earnings of Other Medical Majors at a Glance
Aphria Inc. reported third-quarter fiscal 2020 adjusted EPS of 2 cents in contrast to the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen Inc. (BIIB - Free Report) currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly and Company (LLY - Free Report) delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
NuVasive's (NUVA) Q1 Earnings Beat Estimates, Revenues Miss
NuVasive, Inc. delivered first-quarter 2020 adjusted earnings per share (EPS) of 48 cents, reflecting a 9.4% decline from the year-ago quarter. However, the figure surpassed the Zacks Consensus Estimate by 37.1%. The one-time adjustments include expenses associated with certain ongoing litigation matters and amortization expenses among others.
On a reported basis, EPS came in at 10 cents, reflecting 44.4% decline from the year-ago number.
The year-over-yeardecline can be attributed to significantly lower revenues on a year-over-year basis due to the coronavirus outbreak.
Revenues in the first quarter totaled $259.9 million, down 5.4% year over year on a reported basis (down 5.1% at constant exchange rate or CER). The top line also lagged the Zacks Consensus Estimate by 2.6%.
Geographical & Segmental Details
In the reported quarter, the U.S. Spinal Hardware business revenues declined 6.3% year over year to $138.5 million. The company noted that in the first two months of the quarter, NuVasive's X360 system was tracking to deliver solid year-over-year growth. However, starting in mid-March, the U.S. Spinal Hardware business witnessed significant deferrals in elective surgical procedures due to COVID-19.
NuVasive Inc Price, Consensus and EPS Surprise
NuVasive Inc price-consensus-eps-surprise-chart | NuVasive Inc Quote
Revenues from the U.S. Surgical Support business were $64.3 million in the first quarter, down 10.9% year over year. Here too, Case volumes tracked up year over year in January and February. The business experienced a slowdown in volumes in mid-March due to the pandemic.
In the March-end quarter, the company registered international revenues of $57.1 million, reflecting 4.1% year-over-year growth at CER.This was driven by mid-double-digit growth in Asia-Pacific, led by Japan, where COVID-19 impact was nominal in this period.
Margin Details
In the reported quarter, gross profit declined 6.1% year over year to $188 million. Gross margin contracted 54 basis points (bps) to 72.3%. Adjusted operating profit improved 5% from the year-ago period to $39.5 million. Accordingly, adjusted operating margin expanded 151 bps to 15.2% in the January-March quarter.
Operational Update
The company exited the first quarter with cash and cash equivalents of $511.9 million compared with $213 million at the end of 2019. First-quarter net cash, provided by operating activities, totaled $5.2 million compared with the prior year period’s $24.5 million.
Guidance for 2020
On Apr 14, 2020, while announcing its COVID-19 business update, NuVasive noted that it iscurrently unable to predict the time and rate of recovery of its elective surgery volumes. This compelled the company to withdraw its 2020 guidance.
Our Take
NuVasive witnessed a significant fall in elective procedure volumes in the first quarter, which is expected to intensify in second-quarter 2020.
Given the adverse impact of the coronavirus pandemic on demand for elective surgical procedures, NuVasive is adopting measures to control its expenses and overcome the situation. However, given that technological innovation is the key growth driver, NuVasive intends to maintain its levels of R&D investment.
NuVasive currently carries a Zacks Rank #4 (Sell).
Earnings of Other Medical Majors at a Glance
Aphria Inc. reported third-quarter fiscal 2020 adjusted EPS of 2 cents in contrast to the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million outpaced the consensus estimate by 14.6%. The company carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen Inc. (BIIB - Free Report) currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly and Company (LLY - Free Report) delivered first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>